Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride ... The company acquired ...
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Supernus will ...
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson’s disease. Supernus will make ONAPGO available ...
Parkinson’s Disease Companies are UCB Biopharma SRL, Novartis, Annovis Bio, Supernus ... SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion ...
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease. Supernus on Tuesday said the FDA green light makes Onapgo ...
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Supernus will make ...